A high expression of these signature genes was associated with poor survival in primary NB but also with MEK1/2 and ERK1/2 phosphorylation and sensitivity to different MEK1/2 inhibitors in cell lines [30]. The gene discussed is MAP2K1; the disease is neuroblastoma.